The pharmaceutical giant narrowed its full-year guidance after its blockbuster Wegovy weight-loss drug beat sales expectations in the third quarter.
The pharmaceutical giant narrowed its full-year guidance after its blockbuster Wegovy weight-loss drug beat sales expectations in the third quarter.